|
| 36370950 | MEFIB vs. MAST and FAST: Not a competition but useful tools. | J Hepatol | 2024 |
| 37904314 | Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. | Aliment Pharmacol Ther | 2024 |
| 38061448 | NIS2+<sup>TM</sup> as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials. | J Hepatol | 2024 |
| 37786277 | Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. | Aliment Pharmacol Ther | 2024 |
| 37505221 | Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF). | Hepatology | 2024 |
| 37877759 | Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum. | Aliment Pharmacol Ther | 2024 |
| 37088458 | Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. | Clin Gastroenterol Hepatol | 2024 |
| 37088457 | Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. | Clin Gastroenterol Hepatol | 2024 |
| 37364816 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | Ann Hepatol | 2024 |
| 35074532 | Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. | Clin Gastroenterol Hepatol | 2023 |
| 37802088 | Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. | Lancet Gastroenterol Hepatol | 2023 |
| 37517454 | Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. | J Hepatol | 2023 |
| 37845512 | Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. | Nat Med | 2023 |
| 35809234 | Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis. | Hepatology | 2023 |
| 35478412 | NAFLD-related hepatocellular carcinoma: The growing challenge. | Hepatology | 2023 |
| 36958367 | Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. | Lancet Gastroenterol Hepatol | 2023 |
| 37290471 | Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. | Lancet Gastroenterol Hepatol | 2023 |
| 37059159 | Clinical Trial Landscape in NASH. | Clin Gastroenterol Hepatol | 2023 |
| 37121437 | An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. | J Hepatol | 2023 |
| 37141504 | Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores. | Hepatol Commun | 2023 |
| 37364790 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | J Hepatol | 2023 |
| 37363821 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | Hepatology | 2023 |
| 37356033 | Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. | N Engl J Med | 2023 |
| 37224923 | NIS2+⿢, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study. | J Hepatol | 2023 |
| 36994719 | Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study. | Hepatology | 2023 |
| 36750244 | Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. | Gut | 2023 |
| 36813013 | MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death. | Clin Gastroenterol Hepatol | 2023 |
| 36647687 | Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. | Aliment Pharmacol Ther | 2023 |
| 36513186 | A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. | J Hepatol | 2023 |
| 36804402 | Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). | J Hepatol | 2023 |
| 36894650 | Challenges and opportunities in NASH drug development. | Nat Med | 2023 |
| 36526000 | NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned. | J Hepatol | 2023 |
| 36334688 | Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. | J Hepatol | 2023 |
| 36328331 | NASH cirrhosis trials and major adverse liver outcomes: Big data needed. | J Hepatol | 2023 |
| 36082508 | Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial. | Hepatology | 2023 |
| 36251413 | Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. | J Clin Gastroenterol | 2023 |
| 36375686 | Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. | J Hepatol | 2023 |
| 34329774 | Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. | Clin Gastroenterol Hepatol | 2022 |
| 35710299 | Current therapies and new developments in NASH. | Gut | 2022 |
| 35725922 | Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. | Nat Med | 2022 |
| 35367282 | A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. | J Hepatol | 2022 |
| 35527706 | Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018. | Hepatol Commun | 2022 |
| 36644237 | A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. | JHEP Rep | 2022 |
| 36466104 | Comparison of Clinical, Biochemical, and Histopathologic Profiles between NAFLD in Asian-Indians and United States Adults. | Euroasian J Hepatogastroenterol | 2022 |
| 36527256 | Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH. | Expert Opin Investig Drugs | 2022 |
| 36271849 | Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH. | Hepatol Commun | 2022 |
| 36327436 | A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis. | Am J Gastroenterol | 2022 |
| 36157876 | Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States. | World J Hepatol | 2022 |
| 35090960 | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. | J Hepatol | 2022 |
| 35332569 | Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. | Hepatology | 2022 |